ATOS - アトッサ・ジェネティクス (Atossa Genetics Inc.) アトッサ・ジェネティクス

 ATOSのチャート


 ATOSの企業情報

symbol ATOS
会社名 Atossa Genetics Inc (アトッサ・ジェネティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 アトッサ・ジェネティクス(Atossa Genetics Inc.)は開発段階のヘルスケア企業であり、乳癌の前駆体を検出することができる診断テストの商用化、及び前癌病変の治療の研究・開発・究極の実用化を経由して、乳がんの予防に取り組む。同社の診断テストは米国食品医薬品局(FDA)によって認可された医療機器で構成され、乳房の乳管から流体試料を採取することができる。95%以上の乳がんは乳管で発生する。平成24年9月期決算期において、同社が提供する、及び開発中のテストは「ForeCYTE」、「ArgusCYTE」、「FullCYTE」及び「NextCYTE」を含んでいる。平成24年9月、同社はAcueityのすべての資産を買収した。「MASCT」「Oxy-MASCT」、社名及びロゴはトレードマークである。「ForeCYTE」、「FullCYTE」、「NextCYTE」及び「ArgusCYTE」は同社のサービスマークである。   アトッサ・ジェネティクスは米国のヘルスケア企業。研究サ―ビス、医療デバイスの開発、及び、乳房の健康を改善することに焦点を当てる。開発中の製品には、細胞学検査のための胸部吸引装置「ForeCYTE 」及び、導管洗浄のための導管マイクロカテ―テル「FullCYTE」、また胸部手術のための様々な内視鏡がある。本社はシアトル。   Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
本社所在地 2300 Eastlake Ave. East Suite 200 Seattle WA 98102 USA
代表者氏名 Steven C. Quay スティーブンC.キー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 206-588-0256
設立年月日 39904
市場名 NASDAQ Small Cap
ipoyear 2012年
従業員数 7人
url www.atossagenetics.com
nasdaq_url https://www.nasdaq.com/symbol/atos
adr_tso
EBITDA EBITDA(百万ドル) -9.54782
終値(lastsale) 1.6354
時価総額(marketcap) 8994700
時価総額 時価総額(百万ドル) 8.46616
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -1.53646
当期純利益 当期純利益(百万ドル) -14.97660
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Atossa Genetics Inc revenues was not reported. Net loss applicable to common stockholders increased 66% to $10.8M. Higher net loss reflects General and administrative increase of 83% to $4.1M (expense) Research and development increase of 42% to $1.9M (expense) Other expense net remaining flat at $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$13.85 to -$3.61.

 ATOSのテクニカル分析


 ATOSのニュース

   Atos makes three more acquistions while reporting a drop in revenue  2021/04/20 07:20:52 Economic Times India
Atos' acquisitions of Canada's Processia, UK-based Ipsotek and German cybersecurity firm Cryptovision come months after the IT firm discontinued talks to buy US-based DXC Technology in an over $10-billion deal.
   French IT firm Atos buys further three companies, posts first quarter sales drop  2021/04/20 05:20:27 Investing.com
https://www.investing.com/news/stock-market-news/french-it-firm-atos-buys-further-three-companies-posts-first-quarter-sales-drop-2478981
   What's Happening With ATOS Stock And FAMI Stock Monday?  2021/03/22 13:57:40 Benzinga
Atossa Therapeutics Inc (NASDAQ: ATOS ) shares … Full story available on Benzinga.com
   Moro Hub deploys Google Cloud’s Anthos in region's first solar-powered Data Centre  2021/03/22 12:05:05 Mubasher Info
UAE - Mubasher: Moro Hub, a subsidiary of Digital DEWA, has adopted Google Cloud’s Anthos, a hybrid and multi-cloud platform, in its first solar-powered Green Data Centre in the region, in partnership with Atos. Google Anthos is created to enable …
   Atos appoints Carol Houle global head, consulting and marketing, FS and insurance  2021/03/18 15:22:00 Finextra Research
Atos has announced a significant new appointment to its global Financial Services and Insurance (FS&I) division, with the appointment of Carol Houle as Global Head of Consulting and Marketing.
   What's Happening With ATOS Stock And FAMI Stock Monday?  2021/03/22 13:57:40 Benzinga
Atossa Therapeutics Inc (NASDAQ: ATOS ) shares … Full story available on Benzinga.com
   Moro Hub deploys Google Cloud’s Anthos in region's first solar-powered Data Centre  2021/03/22 12:05:05 Mubasher Info
UAE - Mubasher: Moro Hub, a subsidiary of Digital DEWA, has adopted Google Cloud’s Anthos, a hybrid and multi-cloud platform, in its first solar-powered Green Data Centre in the region, in partnership with Atos. Google Anthos is created to enable …
   Atos appoints Carol Houle global head, consulting and marketing, FS and insurance  2021/03/18 15:22:00 Finextra Research
Atos has announced a significant new appointment to its global Financial Services and Insurance (FS&I) division, with the appointment of Carol Houle as Global Head of Consulting and Marketing.
   Analyzing Veru (NASDAQ:VERU) & Atossa Therapeutics (NASDAQ:ATOS)  2021/03/11 11:14:41 Modern Readers
Atossa Therapeutics (NASDAQ:ATOS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Volatility & Risk Atossa Therapeutics has a beta of 2.34, suggesting that its share price is […]
   31 Stocks Moving in Wednesday's Pre-Market Session  2021/03/10 12:19:45 Benzinga
Gainers MediciNova, Inc. (NASDAQ: MNOV ) shares rose 79.6% to $10.20 in pre-market trading after the biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas. Exela Technologies, Inc. (NASDAQ: XELA ) rose 72.9% to $7.97 in pre-market trading. Exela Technologies shares jumped 179% on Tuesday after the company said it won a 10-year, $90-million contract delivering data transformation solutions for a major US insurer. Obalon Therapeutics, Inc. (NASDAQ: OBLN ) rose 50% to $5.31 in pre-market trading after climbing 18% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) shares rose 40.3% to $3.48 in pre-market trading after gaining over 16% on Tuesday. Atossa Therapeutics, last month, announced final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19..
   What's Happening With ATOS Stock And FAMI Stock Monday?  2021/03/22 13:57:40 Benzinga
Atossa Therapeutics Inc (NASDAQ: ATOS ) shares … Full story available on Benzinga.com
   Moro Hub deploys Google Cloud’s Anthos in region's first solar-powered Data Centre  2021/03/22 12:05:05 Mubasher Info
UAE - Mubasher: Moro Hub, a subsidiary of Digital DEWA, has adopted Google Cloud’s Anthos, a hybrid and multi-cloud platform, in its first solar-powered Green Data Centre in the region, in partnership with Atos. Google Anthos is created to enable …
   Atos appoints Carol Houle global head, consulting and marketing, FS and insurance  2021/03/18 15:22:00 Finextra Research
Atos has announced a significant new appointment to its global Financial Services and Insurance (FS&I) division, with the appointment of Carol Houle as Global Head of Consulting and Marketing.
   Analyzing Veru (NASDAQ:VERU) & Atossa Therapeutics (NASDAQ:ATOS)  2021/03/11 11:14:41 Modern Readers
Atossa Therapeutics (NASDAQ:ATOS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Volatility & Risk Atossa Therapeutics has a beta of 2.34, suggesting that its share price is […]
   31 Stocks Moving in Wednesday's Pre-Market Session  2021/03/10 12:19:45 Benzinga
Gainers MediciNova, Inc. (NASDAQ: MNOV ) shares rose 79.6% to $10.20 in pre-market trading after the biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas. Exela Technologies, Inc. (NASDAQ: XELA ) rose 72.9% to $7.97 in pre-market trading. Exela Technologies shares jumped 179% on Tuesday after the company said it won a 10-year, $90-million contract delivering data transformation solutions for a major US insurer. Obalon Therapeutics, Inc. (NASDAQ: OBLN ) rose 50% to $5.31 in pre-market trading after climbing 18% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) shares rose 40.3% to $3.48 in pre-market trading after gaining over 16% on Tuesday. Atossa Therapeutics, last month, announced final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19..

 関連キーワード  (先端医療機器_テクノロジ― 米国株 アトッサ・ジェネティクス ATOS Atossa Genetics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)